Lung Cancer Screening Software Market Size, Share & Trends Analysis Report By Region (North America (U.S., Canada, Mexico), APAC, Europe, Latin America, MEA), And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 3 Business Days
Lung Cancer Diagnostics Market Growth & Trends
The global lung cancer diagnostics market is expected to reach USD 7.26 billion by 2030, registering a CAGR of 6.5% from 2024 to 2030, according to a new report by Grand View Research Inc. The development of lung cancer-specific biomarkers is one of the primary factors for the growth of the lung cancer diagnostics market over the forecast period. These diagnostic tools facilitate the personalized treatment approach of lung malignancies.
Various biomarkers are present in the research pipeline. For instance, in November 2015, Epigenomics AG announced the launch of a new blood-based test using DNA methylation biomarkers, the development of which is underway. The initial results of this test revealed a promising outcome in the early diagnosis of lung cancer.
Furthermore, various awareness programs focusing on lung cancer and its associated symptoms are initiated in an attempt to elevate the screening and diagnosis rates inindividuals at a high risk of developing lung malignancies. For instance, November is considered as a lung cancer awareness month across the UK, which is supported by the Roy Castle Lung Cancer Foundation.
Lung Cancer Diagnostics Market Report Highlights
Lung Cancer Diagnostics Market Growth & Trends
The global lung cancer diagnostics market is expected to reach USD 7.26 billion by 2030, registering a CAGR of 6.5% from 2024 to 2030, according to a new report by Grand View Research Inc. The development of lung cancer-specific biomarkers is one of the primary factors for the growth of the lung cancer diagnostics market over the forecast period. These diagnostic tools facilitate the personalized treatment approach of lung malignancies.
Various biomarkers are present in the research pipeline. For instance, in November 2015, Epigenomics AG announced the launch of a new blood-based test using DNA methylation biomarkers, the development of which is underway. The initial results of this test revealed a promising outcome in the early diagnosis of lung cancer.
Furthermore, various awareness programs focusing on lung cancer and its associated symptoms are initiated in an attempt to elevate the screening and diagnosis rates inindividuals at a high risk of developing lung malignancies. For instance, November is considered as a lung cancer awareness month across the UK, which is supported by the Roy Castle Lung Cancer Foundation.
Lung Cancer Diagnostics Market Report Highlights
- The non-small cell lung cancer (NSCLC) segment dominated with a substantial revenue share in 2023. NSCLC is further trifurcated into squamous cell carcinoma, adenocarcinoma, and large cell carcinoma of the lung.
- EGFR mutation tests dominated the market with a 29.2% market share for 2023. Epidermal Growth Factor Receptor (EGFR) is one of the most prevalent actionable mutations in patients with NSCLC.
- The hospitals and clinics segment dominated the market in 2023. This is attributed to the facilities with superior diagnostic tools and imaging technologies accounting for accurate lung cancer detection and staging.
- North America dominated the global lung cancer diagnostics market in 2023 due to its advanced healthcare infrastructure, high healthcare spending, and strong reimbursement regulations for cancer diagnostics.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. LUNG CANCER SCREENING SOFTWARE MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Thousands)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Lung Cancer Screening Software Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
CHAPTER 4. LUNG CANCER SCREENING SOFTWARE MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
4.1. Lung Cancer Screening Software Market Share, By Region, 2023 & 2030, USD Thousands
4.2. North America
4.2.1. North America Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.2.2. U.S.
4.2.2.1. U.S. Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.2.3. Canada
4.2.3.1. Canada Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.2.4. Mexico
4.2.4.1. Mexico Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.3. Europe
4.3.1. Europe Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.3.2. U.K.
4.3.2.1. U.K. Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.3.3. Germany
4.3.3.1. Germany Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.3.4. France
4.3.4.1. France Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.3.5. Spain
4.3.5.1. Spain Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.3.6. Italy
4.3.6.1. Italy Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.3.7. Russia
4.3.7.1. Russia Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.4. Asia Pacific
4.4.1. Asia Pacific Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.4.2. China
4.4.2.1. China Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.4.3. Japan
4.4.3.1. Japan Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.4.4. Australia
4.4.4.1. Australia Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.5. Latin America
4.5.1. Latin America Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.5.2. Brazil
4.5.2.1. Brazil Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.6. Middle East and Africa
4.6.1. Middle East and Africa Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.6.2. South Africa
4.6.2.1. South Africa Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
CHAPTER 5. COMPETITIVE LANDSCAPE
5.1. Recent Developments & Impact Analysis by Key Market Participants
5.2. Company Categorization
5.3. Company Heat Map Analysis
5.4. Company Profiles
5.4.1. Nuance Communications, Inc.
5.4.1.1. Participant’s Overview
5.4.1.2. Financial Performance
5.4.1.3. Product Benchmarking
5.4.1.4. Recent Developments/ Strategic Initiatives
5.4.2. MRS
5.4.2.1. Participant’s Overview
5.4.2.2. Financial Performance
5.4.2.3. Product Benchmarking
5.4.2.4. Recent Developments/ Strategic Initiatives
5.4.3. Voxel Cloud
5.4.3.1. Participant’s Overview
5.4.3.2. Financial Performance
5.4.3.3. Product Benchmarking
5.4.3.4. Recent Developments/ Strategic Initiatives
5.4.4. Eon
5.4.4.1. Participant’s Overview
5.4.4.2. Financial Performance
5.4.4.3. Product Benchmarking
5.4.4.4. Recent Developments/ Strategic Initiatives
5.4.5. Koninklijke Philips N.V.
5.4.5.1. Participant’s Overview
5.4.5.2. Financial Performance
5.4.5.3. Product Benchmarking
5.4.5.4. Recent Developments/ Strategic Initiatives
5.4.6. Siemens Healthineers AG
5.4.6.1. Participant’s Overview
5.4.6.2. Financial Performance
5.4.6.3. Product Benchmarking
5.4.6.4. Recent Developments/ Strategic Initiatives
5.4.7. PENRAD
5.4.7.1. Participant’s Overview
5.4.7.2. Financial Performance
5.4.7.3. Product Benchmarking
5.4.7.4. Recent Developments/ Strategic Initiatives
5.4.8. MagView
5.4.8.1. Participant’s Overview
5.4.8.2. Financial Performance
5.4.8.3. Product Benchmarking
5.4.8.4. Recent Developments/ Strategic Initiatives
5.4.9. FUJIFILM Holdings Corporation
5.4.9.1. Participant’s Overview
5.4.9.2. Financial Performance
5.4.9.3. Product Benchmarking
5.4.9.4. Recent Developments/ Strategic Initiatives
5.4.10. Medtronic
5.4.10.1. Participant’s Overview
5.4.10.2. Financial Performance
5.4.10.3. Product Benchmarking
5.4.10.4. Recent Developments/ Strategic Initiatives
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. LUNG CANCER SCREENING SOFTWARE MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Thousands)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Lung Cancer Screening Software Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
CHAPTER 4. LUNG CANCER SCREENING SOFTWARE MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
4.1. Lung Cancer Screening Software Market Share, By Region, 2023 & 2030, USD Thousands
4.2. North America
4.2.1. North America Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.2.2. U.S.
4.2.2.1. U.S. Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.2.3. Canada
4.2.3.1. Canada Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.2.4. Mexico
4.2.4.1. Mexico Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.3. Europe
4.3.1. Europe Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.3.2. U.K.
4.3.2.1. U.K. Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.3.3. Germany
4.3.3.1. Germany Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.3.4. France
4.3.4.1. France Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.3.5. Spain
4.3.5.1. Spain Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.3.6. Italy
4.3.6.1. Italy Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.3.7. Russia
4.3.7.1. Russia Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.4. Asia Pacific
4.4.1. Asia Pacific Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.4.2. China
4.4.2.1. China Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.4.3. Japan
4.4.3.1. Japan Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.4.4. Australia
4.4.4.1. Australia Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.5. Latin America
4.5.1. Latin America Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.5.2. Brazil
4.5.2.1. Brazil Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.6. Middle East and Africa
4.6.1. Middle East and Africa Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
4.6.2. South Africa
4.6.2.1. South Africa Lung Cancer Screening Software Market Estimates and Forecasts, 2018 - 2030 (USD Thousands)
CHAPTER 5. COMPETITIVE LANDSCAPE
5.1. Recent Developments & Impact Analysis by Key Market Participants
5.2. Company Categorization
5.3. Company Heat Map Analysis
5.4. Company Profiles
5.4.1. Nuance Communications, Inc.
5.4.1.1. Participant’s Overview
5.4.1.2. Financial Performance
5.4.1.3. Product Benchmarking
5.4.1.4. Recent Developments/ Strategic Initiatives
5.4.2. MRS
5.4.2.1. Participant’s Overview
5.4.2.2. Financial Performance
5.4.2.3. Product Benchmarking
5.4.2.4. Recent Developments/ Strategic Initiatives
5.4.3. Voxel Cloud
5.4.3.1. Participant’s Overview
5.4.3.2. Financial Performance
5.4.3.3. Product Benchmarking
5.4.3.4. Recent Developments/ Strategic Initiatives
5.4.4. Eon
5.4.4.1. Participant’s Overview
5.4.4.2. Financial Performance
5.4.4.3. Product Benchmarking
5.4.4.4. Recent Developments/ Strategic Initiatives
5.4.5. Koninklijke Philips N.V.
5.4.5.1. Participant’s Overview
5.4.5.2. Financial Performance
5.4.5.3. Product Benchmarking
5.4.5.4. Recent Developments/ Strategic Initiatives
5.4.6. Siemens Healthineers AG
5.4.6.1. Participant’s Overview
5.4.6.2. Financial Performance
5.4.6.3. Product Benchmarking
5.4.6.4. Recent Developments/ Strategic Initiatives
5.4.7. PENRAD
5.4.7.1. Participant’s Overview
5.4.7.2. Financial Performance
5.4.7.3. Product Benchmarking
5.4.7.4. Recent Developments/ Strategic Initiatives
5.4.8. MagView
5.4.8.1. Participant’s Overview
5.4.8.2. Financial Performance
5.4.8.3. Product Benchmarking
5.4.8.4. Recent Developments/ Strategic Initiatives
5.4.9. FUJIFILM Holdings Corporation
5.4.9.1. Participant’s Overview
5.4.9.2. Financial Performance
5.4.9.3. Product Benchmarking
5.4.9.4. Recent Developments/ Strategic Initiatives
5.4.10. Medtronic
5.4.10.1. Participant’s Overview
5.4.10.2. Financial Performance
5.4.10.3. Product Benchmarking
5.4.10.4. Recent Developments/ Strategic Initiatives
